When Your Body Lies to the Doctor (And the Doctor Believes It)

Episode Script

Thanks Toni. We've got a good one today — a little eclectic, but in a way that actually tracks if you're thinking about midlife health as a whole system.

Three things on the table. Muscle fatigue and what a fast-walking study tells us about middle-aged women's bodies. Blood pressure — specifically the gap between having it and knowing you have it. And a case report about a uterine cancer that traveled to the lung and nearly got misidentified as something else entirely. That last one is the one that sat with me.

Let's start with the muscle fatigue research, because it's genuinely interesting and it's the kind of finding that explains something a lot of women already sense but can't quite articulate.

The study is from Buford and colleagues, published this month. They looked at what's called non-local muscle fatigue — which is a real phenomenon and worth understanding. When you work one muscle group hard enough, you don't just fatigue that group. There's a measurable performance drop in muscles that weren't directly involved in the effort. Your legs tire out your arms. Your trunk work affects your grip. It's not imagined and it's not just general tiredness — it's a specific neuromuscular effect that researchers have been studying for a while.

What Buford's team did was compare young women and middle-aged women after a bout of fast-paced walking. Not a marathon. Not a HIIT class. Walking at a fast pace. And what they found was that middle-aged women showed greater non-local muscle fatigue than younger women after the same effort.

I want to be careful here about how to frame this, because the obvious misread is: middle-aged women are weaker or less fit. That's not what this says. What it says is that the same workload — identical in pace and duration — taxes the neuromuscular system differently depending on where you are in life. The effort is the same. The systemic cost is different.

For women in perimenopause and beyond, this actually matters practically. If you've noticed that a walk that should feel easy wipes you out in ways you can't fully account for, this might be part of why. The fatigue isn't just local to your legs. Your system is working harder to manage it. And that has implications for how you structure recovery — not as a sign to do less, but as a reason to take recovery as seriously as the workout itself.

The study doesn't give us sample sizes large enough to draw sweeping conclusions, and it's worth noting this is an area where more research on midlife women specifically is genuinely needed. Most exercise physiology research has historically been done on young men or young women, and the hormonal shifts of perimenopause and menopause are rarely controlled for in study design. So: real finding, worth paying attention to, but one piece of a larger picture we're still building.

Now — blood pressure.

The paper this week is a population-based cross-sectional study out of Southwest Iran, published in 2026, looking at the prevalence of hypertension and — this is the part that matters — the gap between having it and being aware of it. Raeisi Zadeh and colleagues found, consistent with a lot of global hypertension data, that a meaningful portion of people with elevated blood pressure simply didn't know. They were walking around with hypertension, undiagnosed, untreated.

This is not a new finding as a concept. But it keeps showing up in study after study across different populations and geographies, and I think that repetition is itself the message. The awareness gap is real and it's persistent.

For women in midlife, this deserves specific attention. Estrogen has a protective effect on blood vessel function and blood pressure regulation. As estrogen declines through perimenopause, that protection diminishes. Blood pressure tends to creep up in the years around menopause — sometimes gradually enough that it doesn't feel like anything is changing. You feel fine. Your energy is what it always was, roughly. But your cardiovascular numbers are quietly shifting.

The standard advice here is not complicated: know your numbers. Get it checked. Don't assume that because you don't feel symptomatic, your blood pressure is fine. Hypertension earns the nickname "silent killer" for a reason — it's not a condition that announces itself with symptoms until it does, and by then it's doing the kind of work on your arteries and heart that takes years to undo.

I'll say something a little pointed here: the five-minute primary care appointment is not well designed for this kind of monitoring. Women going in to talk about hot flashes or brain fog or sleep disruption are often not getting a full cardiovascular workup in the same visit. Those conversations are treated as separate. And for women in their late 40s and 50s, they really shouldn't be. Menopause is a cardiovascular event as much as it's a reproductive one, and the medical system hasn't fully caught up to that framing.

If your doctor isn't checking your blood pressure at menopause-related appointments, ask. It's a simple measurement with real stakes.

The endometrioid carcinoma case report is the one I want to spend the most time on, because the clinical implication is specific and the stakes are high.

The paper, from Dinh and colleagues, published July 28th, describes a case of high-grade endometrioid carcinoma — that's a type of uterine cancer — that metastasized to the lung. Not unusual in itself; endometrial cancers can and do spread. What made this case notable is the morphology. When pathologists looked at the lung tumor, it had what the paper describes as pilomatrix carcinoma-like morphology — a cellular pattern that closely resembles non-small cell lung carcinoma. A different cancer. A different origin. A different treatment entirely.

The concern the authors raise is misdiagnosis. If a pathologist sees a lung tumor with this pattern and doesn't know to look for a uterine primary — or if the patient's gynecologic history isn't in front of them — they might classify it as a primary lung cancer and treat accordingly. That's not a small error. First-line treatment for non-small cell lung carcinoma and treatment for metastatic endometrioid carcinoma are not the same. Getting this wrong doesn't just mean a suboptimal outcome. It potentially means treating the wrong disease while the actual disease continues.

This is a case report, so I'm not going to overstate the prevalence. Case reports exist to flag rare but clinically significant patterns — they're essentially the medical literature's way of saying "this happened, other clinicians need to know it can happen." The value isn't epidemiological. It's a heads-up.

The practical implication for women who've had endometrial or endometrioid cancer: if a lung lesion ever turns up, the origin of that lesion matters enormously. Make sure your oncologist and any pathologists involved in a biopsy have your full gynecologic history. Advocate for immunohistochemical staining and molecular workup to confirm origin — that's the kind of testing that distinguishes a uterine metastasis from a primary lung tumor. Don't assume the pathologist reading a lung biopsy is automatically thinking about a uterine primary. Sometimes they need to be prompted.

The broader issue here is one that comes up in women's cancer care repeatedly: the siloing of specialties. A pulmonologist looking at a lung mass may not be thinking gynecologic oncology. A pathologist receiving a lung biopsy may not have the patient's full history. The systems aren't always talking to each other, and in rare but real cases like this one, that gap costs something significant.

It's the kind of error that's preventable with better cross-specialty communication and with patients themselves being advocates for their own history being part of every clinical conversation.

---

Sources curated automatically by the Hot Flasher pipeline.